期刊文献+

营养补偿和代谢控制提高细胞蛋白表达的研究 被引量:1

Study on Increasing the Protein Expression of Cells by Specific Nutrient Compensation and Metabolism Control Strategy
下载PDF
导出
摘要 为解决连续灌注培养产物因营养物质不能有效利用而导致产率偏低的问题,降低生产成本,通过在发酵过程中测定表达重组肿瘤坏死因子受体p75:Fc(TNFRp75:Fc)蛋白的CHO工程细胞株对氨基酸成分的不同消耗速率,定量添加特定氨基酸作为营养补偿,提高了培养基中氨基酸的综合利用效率。同时,在连续灌注过程中通过对葡萄糖补加的限量控制,使培养体系中葡萄糖始终低于0.5 g/L,减少了乳酸蓄积对细胞的毒性作用,从而有效降低了灌注速率。结果显示, 在30L工作体积发酵规模上经过氨基酸补偿和葡萄糖控制的连续灌注培养工艺使最终重组蛋白产率(mg/L)和最终产量较工艺改进前提高2.1倍和3.7倍,分别达到388mg/L和244.4g,生产周期延长了一周。工艺改进前后重组蛋白的唾液酸含量和体外生物比活没有改变。通过营养补偿和代谢控制工艺策略可以有效提高连续灌注培养工艺重组肿瘤坏死因子受体p75:Fc蛋白的产率和产能,从而降低产业化成本。 To increase the productivity and yield Every amino acid consumption rate in continual perfusi of recombinant protein in on culture of engineering continual perfusion processing, CHO cell line which expressed recombinant TNFRp75:Fc fusion protein were analyzed. Then rational amino acids were accordingly added to improve its comprehensive utilizing. At the same time, glucose supply was controlled to make the concentration of glucose below 0.5 g/L for ameliorating the toxicity of lactate accumulation in order to decrease the perfusion rate. The result showed that the productivity of recombinant protein was 3.1 times (388mg/L) and the total yield was 4.7 times (244.4g) that of control cultures after nutrient compensation and metabolism control in 30 liter working volume, and the fermentation period was prolonged one week longer. The sialic acid content and bioactivity in vitro of recombinant TNFRp75 : Fc were not changed after nutrient compensation and glucose control supply. Nutrient compensating and metabolic control in continual perfusion fermentation could significantly increase the productivity and yield of recombinant TNFRp75: Fc, and thus reduced relative industrialization costs.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2006年第4期12-19,共8页 China Biotechnology
基金 国家"863"计划资助项目(2001AA215051 2002AA2Z3309 2005AA2Z3G10)
关键词 营养补偿代谢控制 连续灌注 重组肿瘤坏死因子受体p75:Fc蛋白 产率 Nutrient compensation Metabolism control Continual perfusion Recombinant TNFRp75:Fc Productivity
  • 相关文献

参考文献16

  • 1Xie L Z,Wang D I C.Intergrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells.Tibtech March,1997,15:109 ~ 113
  • 2Bibila T A,Robinson D K.In pursuit of the optimal fed-batch process for monoclonal antibody production.Biotechnol Prog,1995,11:1 ~13
  • 3Ozturk S S.Engineering challenges in high density cell culture systems.Cytotechnology,1996,22:3 ~ 16
  • 4Yabannavar V M,Singh V,Connelly N V.Mammalian cell retention in a spinfilter perfusion bioreactor.Biotechnol Bioeng,1992,40:925 ~ 933
  • 5Smith C A,Davis T,Anderson D,et al.A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.Science,1990,248(4958):1019 ~ 1023
  • 6Jacobs C A,Smith C A.Methods of lowering active TNF-αlevels in mammals using tumor necrosis receptor.United states patent,5605690,Feb 25,1997
  • 7Losman M J,Hansen H J,Dworak H,et al.Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2).Cancer supplement,1997,80(12):2660 ~2666
  • 8Sanders P G,Hussein A,Coggins L,et al.Gene amplification:the Chinese hamster glutamine synthetase gene.Dev Biol Stand,1987,66:55 ~63
  • 9Brown M E,Renner G,Field R P,et al.Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system.Cytotechnology,1992,19:231 ~ 236
  • 10Altamirano C,Paredes C,Illanes A,et al.Strategies for fedbatch cultivation of t-PA producing CHO cells:substitution of glucose and glutamine and rational design of culture medium.Journal of Biotechnology,2004,110:171 ~ 179

同被引文献23

  • 1Chadd H E,Chamow S M.Therapeutic antibody expression technology.Curr Opin Biotechnol,2001,12(2):188 ~ 194
  • 2Brekke O H,Sandlie I.Therapeutic antibodies for human diseases at the dawn of the twenty-first century.Nat Rev Drug Discov,2003,2:52 ~ 62
  • 3Pavlou A K,Belsey M J.The therapeutic antibodies market to 2008.Eur J Pharm Biopharm,2005,59(3):389 ~396
  • 4Sabine L.Can China bring its own pipeline to the market.Nature Biotechnology,2004,22:1497 ~ 1499
  • 5陈志南,邢金良.中国生物技术发展产业报告.北京:化学工业出版社,2004.107~117
  • 6Aldridge S.Biomanufacturing faces new sets of challenges.Genetic Engineering News,2004,24(14):1
  • 7Pavlou A K.Marketspace:The immunotherapies markets,2003-2008.J Commer Biotechnol,2004,10:273 ~278
  • 8Butler M.Animal cell cultures:recent achievements and perspectives in the production of biopharmaceuticals.Appl Microbiol Biotechnol,2005,68:283 ~291
  • 9Datamonitor.Monoclonal antibody therapies:evolving into a $30 billion market.London:Datamonitor Press,2005.103 ~155
  • 10Molowa D T,Mazanet R.The state of biopharmaceutical manufacturing.Biotechnol Annu Rev,2003,9:285 ~ 302

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部